32.26  -5.87 (-15.39%)		10-06 16:00
Open: 38.74 High: 39.61 Volume: 1,550,734		Pre. Close: 38.13 Low: 31.13 Market Cap: 2,236(M)

Short term
Mid term
Targets	6-month :	40.74	1-year :	46.26
Resists	First :	34.88	Second :	39.61
Pivot price	33.27
Supports	First :	27.25	Second :	22.67
MAs	MA(5) :	34.25	MA(20) :	32.02
	MA(100) :	27.18	MA(250) :	0
MACD	MACD :	1	Signal :	0.8
%K %D	K(14,3) :	66.5	D(3) :	66.3
RSI	RSI(14): 49.8
52-week	High :	39.61	Low :	18.85

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ALMR ] has closed above bottom band by 36.3%. Bollinger Bands are 4.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	39.66 - 39.87	39.87 - 40.04
Low:	30.73 - 30.92	30.92 - 31.08
Close:	31.94 - 32.27	32.27 - 32.55

Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.

Tue, 06 Oct 2026
Alamar Biosciences, Inc. (ALMR) Stock Price, News, Quote & History - Yahoo! Finance Canada

Mon, 05 Oct 2026
A former CEO of a cancer-detection company joins Alamar's board. - Stock Titan

Thu, 24 Sep 2026
Alamar Biosciences Study in The Lancet Neurology Finds Distinct Biomarker Responses to Lecanemab in Early Alzheimer’s Disease - Quiver Quantitative

Thu, 24 Sep 2026
Lancet Neurology Study Using Alamar Biosciences’ Technology - GlobeNewswire

Thu, 24 Sep 2026
Among 197 Alzheimer’s patients, 34 of 130 blood markers changed as they received more infusions. - Stock Titan

Sun, 16 Aug 2026
Alamar Biosciences: Promising But Expensive Proteomics Growth - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	69 (M)
Shares Float	36 (M)
Held by Insiders	22.2 (%)
Held by Institutions	58.2 (%)
Shares Short	2,120 (K)
Shares Short P.Month	2,080 (K)

EPS	-0.73
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.51
Profit Margin	-49.5 %
Operating Margin	-46 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	82 %
Gross Profit (p.s.)	0.84
Sales Per Share	1.44
EBITDA (p.s.)	-0.55
Qtrly Earnings Growth	0 %
Operating Cash Flow	-60 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-44.81
PEG Ratio	0
Price to Book value	7.15
Price to Sales	22.29
Price to Cash Flow	-37.11

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.